VOX SANGUINIS is a distinguished peer-reviewed journal in the fields of Hematology and Medicine, published by Wiley, a leading academic publisher based in the United Kingdom. With a rich history dating back to its inception in 1952, this journal has consistently provided a platform for innovative research and insightful reviews, advancing the understanding of blood-related disorders and therapies. As evidenced by its robust performance—ranking #57 out of 137 in Scopus for Medicine in Hematology and holding a Q2 classification in both Hematology and miscellaneous Medicine categories—VOX SANGUINIS is recognized for its significant contributions to the scientific community. This journal serves as a vital resource for researchers, professionals, and students alike, fostering knowledge exchange and collaboration within the field. With its ongoing commitment to quality and integrity, VOX SANGUINIS continues to shape the future of hematological research well into 2024 and beyond.

BLOOD REVIEWS is a highly regarded journal published by Churchill Livingstone, specializing in the fields of Hematology and Oncology. With an impressive Q1 ranking in both disciplines and placing in the top 10% of its peer categories according to Scopus metrics, it provides an essential platform for the dissemination of cutting-edge research and reviews pertaining to blood disorders and cancer treatment. Since its inception in 1987 and continuing through 2024, the journal has established itself as a cornerstone for healthcare professionals, researchers, and students who seek to advance their understanding of hematologic and oncologic topics. While not an open-access journal, BLOOD REVIEWS retains a reputation for delivering high-quality, peer-reviewed articles that foster dialogue and innovation within the scientific community. For those in the United States and beyond, the journal serves as a vital resource, housed at the Journal Production Department in Edinburgh, Scotland, ensuring accessibility and a global reach in its critical academic contributions.

British Journal of Haematology, published by Wiley, is a leading journal in the field of hematology, with an impressive impact factor reflecting its significance in the medical research community. Established in 1955, the journal has consistently contributed to advancing knowledge in hematology, currently holding a prestigious Q1 ranking in the Scopus category of Hematology, placing it in the top 18% of the field. The journal encompasses a broad range of topics including clinical and laboratory aspects of blood disorders and hematological malignancies, making it an essential resource for hematologists, researchers, and healthcare professionals. With its commitment to publishing top-tier research and clinical studies, the British Journal of Haematology plays a critical role in shaping treatment approaches and improving patient outcomes worldwide. Please note that this journal does not offer Open Access options, ensuring that published content is rigorously curated for quality and relevance.

TRANSFUSION MEDICINE, ISSN 0958-7578, is a prestigious journal published by Wiley that focuses on advancing the field of transfusion medicine. Since its inception in 1991, the journal has provided a vital platform for the dissemination of innovative research findings, clinical practices, and policy developments impacting blood transfusion and hematology. With an impressive repository of peer-reviewed articles, TRANSFUSION MEDICINE aims to facilitate the exchange of knowledge among hematologists, transfusion practitioners, and related professionals to enhance patient outcomes. Currently positioned in the third quartile (Q3) of Hematology in the 2023 category rankings, the journal ranks #83 out of 137 in the Scopus database, highlighting its relevance and influence in the field, albeit with a 39th percentile ranking. Although it does not offer open access options, the dissemination of critical findings continues to support the advancement of transfusion practices on a global scale. Researchers, professionals, and students alike are encouraged to engage with the valuable insights published within this journal as it converges to 2024 and beyond.

Hematology Transfusion and Cell Therapy, published by Elsevier, is a leading Open Access journal dedicated to advancing the fields of hematology, immunology, and transfusion medicine. Since its establishment in 2018, this journal has provided a vital platform for sharing innovative research and clinical advancements in the management of blood disorders and cellular therapies. Based in Brazil, it attracts a global audience, facilitating access to high-quality research that influences clinical practice and policy. With a current impact factor that places it in the Q3 category for both hematology and immunology as of 2023, the journal is recognized for its rigorous peer-review process and commitment to disseminating significant findings. By featuring a diverse range of articles, from original research to reviews, Hematology Transfusion and Cell Therapy aims to foster collaboration and knowledge sharing among researchers, professionals, and students alike, empowering them to tackle emerging challenges in their fields.

Blood Transfusion is a leading journal in the fields of Hematology, Immunology, and Medicine, published by SIMTIPRO SRL in Italy. With its ISSN 1723-2007, the journal has established a significant presence in the academic community, as evidenced by its positioning within the Q2 category in Hematology and Medicine (miscellaneous) and Q3 in Immunology and Allergy for 2023. Notably, it ranks #38 out of 137 in the Hematology category, showcasing its impactful contributions to research and practice. Operating under a traditional publishing model, this journal provides valuable insights into advances in blood transfusion science, ultimately aimed at enhancing patient care and outcomes. Spanning from 2003 to 2024, the scope of Blood Transfusion covers a wide range of topics related to hematological and immunological research, making it an essential resource for researchers, healthcare professionals, and students engaged in these critical fields.

TRANSFUSION CLINIQUE ET BIOLOGIQUE, an esteemed journal published by Elsevier France - Éditions Scientifiques Médicales Elsevier, has been a pivotal resource in the fields of transfusion medicine, biochemistry, and hematology since its inception in 1994. With a strong commitment to advancing scientific knowledge, this journal provides a platform for high-quality research and clinical studies aimed at improving patient care and outcomes in transfusion practices. Although categorized in Q3 and Q4 quartiles across multiple categories in Biochemistry and Medicine for 2023, the journal holds significant potential for growth and impact within the scientific community. While it currently does not offer open access options, its indexing in reputable databases ensures visibility and reach among professionals and researchers. As the field evolves, TRANSFUSION CLINIQUE ET BIOLOGIQUE aims to continue fostering innovation and collaboration, making it a valuable tool for anyone involved in medical, biochemical, and hematological research.

Anemia is a distinguished open-access journal published by HINDAWI LTD, focusing on the intricate and vital field of hematology and related disciplines. Since its inception in 2010, this journal has been dedicated to advancing our understanding of blood disorders, with a particular emphasis on anemia, through the dissemination of high-quality research that is freely accessible to a global audience. The journal's evolving scope from its founding through 2024 embodies its commitment to include the latest breakthroughs and methodologies in cell biology and hematological research. With its presence in prestigious databases and a tiered ranking that places it in the Q3 category in Hematology and Q4 in Cell Biology as of 2023, Anemia serves as an invaluable resource for researchers, clinicians, and students alike. The journal is indexed with a respectable position in Scopus, ranking 52 out of 137 in Hematology, highlighting its growing influence in the medical and scientific communities. With continued emphasis on open access, Anemia not only fosters collaborative research but also ensures that crucial findings reach those who need them most, enhancing educational outcomes and clinical practices worldwide.

Hematology is a distinguished open-access journal published by Taylor & Francis Ltd, dedicated to advancing research and knowledge in the field of hematology. Established in 1996, the journal has continually evolved to meet the needs of a growing community of researchers and practitioners, providing a vital platform for disseminating innovative findings and clinical insights. With its impact factor reflecting a robust commitment to quality scholarship, Hematology has achieved a respectable position in its category as evidenced by its Q3 ranking in the Hematology category and ranks #85 out of 137 in the Scopus index, which positions it in the 38th percentile among its peers. The journal’s open-access policy, initiated in 2019, further enhances its reach and accessibility, allowing a broad audience of professionals, researchers, and students to engage with high-quality research without barriers. By covering a wide range of topics related to blood disorders, treatment methodologies, and emerging therapies, Hematology stands as an essential resource for those dedicated to innovation in this critical area of healthcare.

The Egyptian Journal of Haematology, published by WOLTERS KLUWER MEDKNOW PUBLICATIONS, stands as a pivotal resource in the field of hematology, particularly within the context of Egypt and the broader Middle Eastern region. This journal is dedicated to disseminating high-quality research that explores the latest advancements in blood disorders, hematologic malignancies, and transfusion medicine. With a focus on original research, case studies, and reviews, it aims to provide a comprehensive platform for hematologists, researchers, and healthcare professionals to enhance their understanding and management of hematological conditions. Although it is not an open-access journal, the rigorous peer-review process ensures that only the most impactful studies are published, contributing to the journal's reputation in the academic community. The Egyptian Journal of Haematology serves as an essential tool for advancing knowledge, improving clinical outcomes, and fostering collaboration among experts in the field.